Peptides with wide varieties and high-affinities (~nM) can be obtained with high success rate.
- Proprietary mRNA display methods enable efficient screening.
- Practical biosynthesis & assays enable rapid selection and activity based evaluation.
- Innovative improvements in mRNA display enable screening from a library of >10^13 peptide.
- Practical biosynthesis & assays enable rapid selection and activity based evaluation.
Peptides with wide varieties and high-affinities(~nM) can be obtained with high success rate.
Hit peptides have been obtained toward >20 targets with our platform.
High binding affinity was achieved as the Hits in initial screening.
Contact us to discuss your target, project requirements, and discovery strategy.
Explore Fujifilm's peptide discovery platform and proprietary mRNA display technology.
Key topics covered:
- High-affinity peptide discovery
- mRNA display technology
- Discovery workflow
- Track record
Fujifilm offers a comprehensive suite of contract services. Our core offerings include the use of mRNA display technology to discover peptides that bind strongly and specifically to target proteins, combined with rapid structural optimization and activity screening of these hit peptides (e.g., inhibitory activity, selectivity). Additionally, we provide supporting services such as peptide chemical synthesis and the preparation of target proteins.
- Improved mRNA display allows screening from a huge library.
- Many conditions (=cycle size, targets, selections) can be performed in parallel.
A variety of hits have been obtained with a high success rate.
Rapid selection and activity exploration by practical biosynthesis & assay combined with conventional chemical synthesis.
Chemical Synthesis: long lead time (20~30days) and not suited to parallel synthesis/purification.
Biosynthesis: short lead time (5~7days) and suited for parallel preparation (~1,000 peptides/month)
Discuss your peptide discovery project, from hit identification through activity evaluation and optimization.
Diverse binding peptides were successfully obtained toward both of 2 FGFRs (fibroblast growth factor receptor).
- FGFR activatable peptide had been found through rapid and exhaustive cell activity screening with biosynthetic peptides from diverse hit peptides.
- Optimized peptide showed same cell growth rate with the natural protein (bFGF) in MSC (Mesenchymal Stem Cell).
- siRNAs were conjugated to the integrin αvβ3-binding peptide. With this Peptide Oligonucleotide Conjugates, cell-selective target gene knockdown were achieved.
Cell-based screening for GPCRs and other transmembrane targets.
A Cyclic Peptide Discovery Platform for Targeted Nucleic Acid Delivery (Yukiko Ishii, Shin Izuta, Taishi Fuda, Misaki Masui, Nao Yamazaki, Ryo Ukekawa)
- Peptide Discovery Platform for Advancing Peptide-Oligonucleotide Conjugation (Yukiko Ishii, Shin Izuta, Masahiro Kochi, Koo Suzuki)
- Peptide Discovery Platform for Advancing Peptide-Oligonucleotide Conjugation (Yukiko Ishii, Shin Izuta, Masahiro Kochi, Koo Suzuki)
- Cyclic Peptide Discovery Services (Yukiko Ishii, Shin Izuta, Ryota Haba)